
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc. has achieved significant regulatory milestones that enhance its prospects for the approval of its drug OST-HER2 in the treatment of metastatic osteosarcoma, notably through a successful Type C meeting with the FDA and alignment with the UK MHRA. The company’s strategic regulatory positioning, including eligibility for Union-wide marketing authorization in Europe, supports a streamlining of its filing processes and potentially accelerates market entry. Importantly, the innovative mechanism of OST-HER2, targeting critical immune pathways, aligns with emerging oncological research that indicates improved outcomes for osteosarcoma treatment, signaling a promising future for the company.
Bears say
OS Therapies Inc faces significant challenges due to the inherent characteristics of osteosarcoma, which does not effectively respond to receptor-level HER2 inhibition and is characterized as immunologically “cold” and genetically unstable. This complicates the development of targeted therapies, limiting the potential for successful treatment options and market competitiveness. Furthermore, the poor responsiveness of osteosarcoma to antibody biology raises concerns about the viability of the company's product pipeline and its ability to deliver revenue-generating therapies in the near future.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares